Scott Isaacs/LinkedIn
Sep 29, 2026, 16:27
Scott Isaacs: How GLP-1 RAs Target Systemic Inflammation to Drive Cardio, Autoimmune, and Gut Health
Scott Isaacs, Former President of American Association of Clinical Endocrinology (AACE), shared a post on LinkedIn:
“Decreased inflammation from GLP1 RAs leads to more stable plaques, myocardial remodeling, reduced cytokine storm, stronger gut barrier, and decreased immune hyperactivity in the brain and autoimmune disease.”
Title: Anti-inflammatory effects of GLP1-RA drugs
Authors: Luis Quintana, Nadim Tabaza, Berkan Kurt, Florian Kahles
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 29, 2026, 16:21Yitshak Kreiss: From Treating Patients to Defining the Standard of Knowledge
-
Sep 29, 2026, 16:18Edward Lee Carter: Why Periprocedural DOAC Guidance Needs a Common Output Standard
-
Sep 29, 2026, 16:07Yasmine Laraba: Deep Vein Thrombosis Causes, Signs and Management
-
Sep 29, 2026, 16:01Stephen Cornelissen: How Joining the Stem Cell Registry Can Save Patients with Blood Cancers
-
Sep 29, 2026, 15:45Alan Nurden: Could Mast Cell aIIb Integrin Play a Key Role in Septic Thrombus Stability?
-
Sep 29, 2026, 15:43Priyadarshani Sharma: Advocacy and Patient Rights Transform Indian Haemoglobinopathies Care
-
Sep 29, 2026, 15:21Kanchan K Banerjee: Rusfertide Earns NCCN Category 1 Recommendation for Polycythemia Vera
-
Sep 29, 2026, 15:06Faizan KhanÖ‰ The Worldwide Burden of Venous Thromboembolism
-
Sep 29, 2026, 14:59Global Von Willebrand Disease Diversity Webinar Now Available on EHC YouTube – EHC